Lattice Biologics Ltd. (LBLTF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lattice Biologics Ltd. (LBLTF) trades at $0.00 with AI Score 51/100 (Grade B). Lattice Biologics Ltd. is a biotech company specializing in biologic products for bone regeneration across various medical applications. Market cap: $16,545, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for LBLTF: LBLTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LBLTF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
LBLTF: the 6 perspectives are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Lattice Biologics Ltd. (LBLTF) Healthcare & Pipeline Overview
Lattice Biologics Ltd. is a pioneering biotech firm focused on developing and marketing biologic products for bone regeneration, leveraging innovative amniotic fluid technology to address diverse orthopedic and dental needs globally.
What Is the Investment Thesis for LBLTF?
Lattice Biologics Ltd. presents a unique investment thesis driven by its innovative product line and expanding market opportunities in the healthcare sector. The company has reported a gross margin of 41.4%, indicating a strong potential for profitability as it scales its operations. With a negative profit margin of -60.2%, the company is currently in a growth phase, focusing on increasing its market share in the bone regeneration space. The ongoing development of its amniotic fluid-based products is expected to drive revenue growth, particularly in orthopedic and dental markets, which are projected to grow significantly over the next few years. Additionally, the company's diverse product range, including traditional allografts, positions it favorably against competitors. However, potential risks such as regulatory challenges and market competition must be carefully monitored. Overall, Lattice Biologics Ltd. is well-positioned to capitalize on emerging trends in the healthcare sector, making it a noteworthy entity for investors seeking exposure to biotech innovations.
Based on FMP financials and quantitative analysis
LBLTF Key Highlights
- Market Cap: $0.00B, indicating a currently unvalued or inactive trading status.
- Profit Margin: -60.2%, reflecting ongoing investment in growth and development.
- Gross Margin: 41.4%, showcasing efficiency in production and potential for future profitability.
- Beta: 1.21, suggesting higher volatility compared to the market average.
- Dividend Yield: None, as the company does not currently distribute dividends.
Who Are LBLTF's Competitors?
LBLTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABMD Abiomed, Inc. | $381.02 | +0.00% | $17.18B | 60 |
| ISRG Intuitive Surgical, Inc. | $432.83 | +1.60% | $153.29B | 96 |
| SNN Smith & Nephew plc | $30.55 | +0.99% | $12.91B | 50 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LBLTF's Key Strengths?
- Innovative product line with unique amniotic fluid-based solutions.
- Strong gross margin of 41.4%, indicating operational efficiency.
- Diverse range of applications across multiple medical disciplines.
- Established presence in the growing orthopedic and dental markets.
What Are LBLTF's Weaknesses?
- Negative profit margin of -60.2%, indicating financial challenges.
- Limited market capitalization, affecting visibility and investment appeal.
- Dependence on a niche market, which may limit growth potential.
- Potential regulatory hurdles in the biotech industry.
What Could Drive LBLTF Stock Higher?
- Expansion of product offerings in the orthopedic market to capture growing demand.
- Development of innovative amniotic fluid-based products to enhance surgical outcomes.
- Strategic partnerships with healthcare providers to increase market penetration.
- Entry into new geographic markets to broaden customer base and revenue streams.
What Are the Key Risks for LBLTF?
- Financial-distress signal — its Altman Z-Score of -25.57 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges that could delay product approvals.
- Competitive pressures from established medical device companies.
- Market volatility affecting investor sentiment and stock performance.
- Dependence on a niche market may limit growth opportunities.
What Are the Growth Opportunities for LBLTF?
- Growth opportunity 1: The global orthopedic market is projected to grow significantly, with estimates suggesting it could reach $60 billion by 2027. Lattice Biologics Ltd. can capitalize on this growth by expanding its product offerings in bone regeneration, particularly in spinal and orthopedic surgeries, where demand for innovative solutions is rising. The company's unique amniotic fluid-based products position it well to capture market share in this lucrative segment.
- Growth opportunity 2: The dental implant market is anticipated to grow at a CAGR of 6.2% through 2025, driven by an aging population and increasing dental health awareness. Lattice Biologics Ltd. can enhance its presence in this sector by promoting its biologic products, which are designed to support dental procedures. By targeting dental professionals and clinics, the company can leverage this growth trend to expand its customer base.
- Growth opportunity 3: As healthcare providers increasingly adopt regenerative medicine practices, Lattice Biologics Ltd. stands to benefit from the rising demand for biologic products. The market for regenerative medicine is expected to reach $118 billion by 2026, providing a substantial opportunity for the company to position its innovative solutions as essential tools in surgical procedures across various specialties.
- Growth opportunity 4: The increasing prevalence of sports-related injuries is driving demand for advanced treatment options in sports medicine. Lattice Biologics Ltd. can tap into this market by promoting its products for anterior and posterior cruciate ligament repairs. As awareness of the benefits of biologic treatments grows, the company can enhance its market presence and drive sales.
- Growth opportunity 5: The global market for wound care products is projected to reach $20 billion by 2025, fueled by an aging population and rising incidences of chronic wounds. Lattice Biologics Ltd.'s offerings, which enhance wound healing, can be strategically marketed to hospitals and healthcare providers, allowing the company to capture a portion of this expanding market.
What Opportunities Does LBLTF Have?
- Growing demand for orthopedic and dental solutions as the population ages.
- Expansion into new geographic markets to increase sales.
- Rising interest in regenerative medicine and biologic treatments.
- Potential partnerships with healthcare providers for product distribution.
What Threats Does LBLTF Face?
- Intense competition from established medical device companies.
- Regulatory challenges that may impact product approval timelines.
- Market volatility affecting investment and operational stability.
- Rapid technological advancements requiring continuous innovation.
What Are LBLTF's Competitive Advantages?
- Innovative product offerings that differentiate Lattice Biologics from competitors.
- Strong focus on research and development to stay ahead in the market.
- Established relationships with healthcare providers and institutions.
- Specialization in amniotic fluid-based products, a unique niche in the industry.
- Commitment to enhancing patient outcomes through advanced technologies.
What Does LBLTF Do?
Founded in Belgrade, Montana, Lattice Biologics Ltd. is a biotech company dedicated to the development, manufacture, and marketing of biologic products aimed at enhancing bone regeneration in dental, spine, and orthopedic applications. The company has carved a niche in the medical devices sector with its innovative products, including AmnioBoost and AmnioBlast, which are derived from amniotic fluid. These products are designed to support various medical procedures such as spine surgery, breast reconstruction, and orthopedic surgeries, demonstrating versatility in their application. Lattice Biologics also offers a comprehensive range of traditional allografts, including demineralized bone matrix allografts, which are crucial for enhancing surgical outcomes in complex procedures. The company’s commitment to advancing medical technology is evident in its continuous efforts to improve patient care through innovative solutions. With a global reach, Lattice Biologics serves a diverse clientele, addressing critical needs in bone regeneration and healing across multiple medical disciplines. The company’s strategic focus on research and development positions it well within the competitive landscape, as it seeks to expand its product offerings and enhance its market presence.
What Products and Services Does LBLTF Offer?
- Develop biologic products for bone regeneration in dental, spine, and orthopedic applications.
- Manufacture innovative amniotic fluid-based products such as AmnioBoost and AmnioBlast.
- Provide a range of allografts including traditional, spinal, and demineralized bone matrix.
- Market products for various surgical procedures including spine surgery and breast reconstruction.
- Focus on enhancing patient outcomes through advanced medical technologies.
- Serve a global clientele in the healthcare sector.
How Does LBLTF Make Money?
- Generate revenue through the sale of biologic products and allografts.
- Leverage innovative product development to meet the needs of healthcare providers.
- Engage in partnerships with hospitals and clinics for product distribution.
- Focus on research and development to expand the product portfolio.
- Utilize marketing strategies to promote the benefits of biologic solutions.
What Industry Does LBLTF Operate In?
The medical devices industry is experiencing robust growth, driven by advancements in technology and an increasing demand for innovative healthcare solutions. The global market for orthopedic devices is projected to reach approximately $60 billion by 2027, reflecting a compound annual growth rate (CAGR) of around 5%. Lattice Biologics Ltd. operates within this expanding market, focusing on biologic products that enhance bone regeneration—a critical area in orthopedic and dental surgery. The competitive landscape includes established players and emerging biotech firms, with Lattice Biologics differentiating itself through its unique amniotic fluid-based offerings. This strategic positioning allows the company to tap into niche markets and leverage growing trends in regenerative medicine.
Who Are LBLTF's Key Customers?
- Healthcare providers including hospitals and surgical centers.
- Dental professionals seeking advanced solutions for implant procedures.
- Orthopedic surgeons focusing on innovative treatments for bone regeneration.
- Sports medicine practitioners addressing injuries and rehabilitation.
- Patients requiring surgical interventions for various medical conditions.
Company Profile
Lattice Biologics Ltd. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Belgrade, US. The company is led by CEO Donna Medina. LBLTF has traded publicly since 2010.
How Lattice Biologics Ltd. Is Valued
Lattice Biologics Ltd. carries a market capitalization of 17K, placing it in the micro-cap category. Relative to its peer group, LBLTF's quantitative score of 51/100 is below the peer average of 70/100.
ROE 23%Key Financial Metrics
Return on equity for Lattice Biologics Ltd. stands at 23.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -49.1%, showing how much profit it generates from its asset base. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Lattice Biologics Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -25.57 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Lattice Biologics Ltd. revenue of about $9.5M for fiscal 2026, with EPS near $-0.03.
LBLTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests strong confidence in Lattice Biologics' future, indicating that leadership believes in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments and potential market opportunities.
- Increased media coverage around regenerative medicine is boosting visibility for Lattice Biologics, creating a favorable perception among investors.
- Recent partnerships or collaborations have been perceived positively, suggesting that Lattice is positioning itself for growth in a competitive landscape.
Bear Case
- Concerns about regulatory challenges in the biotech sector may weigh on investor sentiment, creating uncertainty around Lattice's product approvals.
- Recent social media discussions reflect skepticism regarding the company's ability to scale operations effectively, which could hinder growth.
- Market perception has been cautious due to broader economic factors affecting biotech stocks, leading to a bearish outlook among some investors.
- Insider selling activity has raised alarms among some community members, indicating potential lack of confidence from insiders in the near-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LBLTF Latest News
No recent news available for LBLTF.
LBLTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LBLTF.
Price Targets
Wall Street price target analysis for LBLTF.
LBLTF MoonshotScore
What does this score mean?
The MoonshotScore rates LBLTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Donna Medina
CEO
Donna Medina has a robust background in the biotech industry, with extensive experience in product development and strategic management. She has held various leadership roles in healthcare companies, focusing on innovation and market expansion. With a strong educational foundation in life sciences, Medina has been instrumental in driving Lattice Biologics Ltd.'s vision and growth.
Track Record: Under Donna Medina's leadership, Lattice Biologics has launched key products that have expanded its market presence. Her strategic decisions have focused on enhancing R&D capabilities and fostering partnerships within the healthcare sector.
LBLTF OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher-tier listings like OTCQX or OTCQB, often resulting in less visibility and liquidity. These companies may have limited financial disclosures, making it essential for investors to conduct thorough due diligence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures may lead to challenges in assessing the company's performance.
- Lower liquidity can result in higher volatility and difficulty in executing trades.
- Regulatory scrutiny may be heightened for companies in the OTC market.
- Market perception issues may arise due to the company's tier classification.
- Review the company's financial statements and disclosures.
- Assess the competitive landscape and market positioning.
- Evaluate the management team's experience and track record.
- Investigate product development pipelines and regulatory status.
- Monitor industry trends and potential market opportunities.
- Established product offerings in the healthcare sector.
- Presence of experienced leadership with a background in biotech.
- Engagement in research and development to drive innovation.
Common Questions About LBLTF (Healthcare)
What does Lattice Biologics Ltd. do?
Lattice Biologics Ltd. specializes in developing and marketing biologic products for bone regeneration. The company focuses on innovative solutions such as amniotic fluid-based products and a variety of allografts, which are used in dental, orthopedic, and spine surgeries. Their offerings aim to enhance surgical outcomes and promote healing across multiple medical applications.
What are the key growth opportunities for LBLTF in healthcare?
Lattice Biologics Ltd. has several growth opportunities, particularly in the expanding orthopedic and dental markets. The global orthopedic market is projected to grow significantly, and the company can leverage its innovative biologic products to capture market share. Additionally, the rising interest in regenerative medicine presents further avenues for growth, allowing Lattice Biologics to expand its product offerings and reach new customer segments.
What are the main risks for LBLTF?
Lattice Biologics Ltd. faces several risks, including regulatory challenges that may impact product approval timelines and market entry. The company also contends with intense competition from established players in the medical devices industry, which could affect its market share. Furthermore, market volatility may influence investor sentiment and stock performance, necessitating careful monitoring of external economic factors.
What are the key factors to evaluate for LBLTF?
Lattice Biologics Ltd. (LBLTF) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does LBLTF data refresh on this page?
LBLTF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LBLTF's recent stock price performance?
Lattice Biologics Ltd. (LBLTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product line with unique amniotic fluid-based solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LBLTF overvalued or undervalued right now?
Valuing Lattice Biologics Ltd. (LBLTF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LBLTF?
Before investing in Lattice Biologics Ltd. (LBLTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial disclosures may affect the assessment of the company's performance.